


RECEIVED

APR 22 2002

Atty. Docket No.: 215101.01501

Customer No. 27160

TECH CENTER 1600/2900 PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

William S. DALTON et al.

Serial No. 10/024,017

Group Art Unit: 1646

Filed: December 21, 2001

Examiner: Unknown

FOR: COMPOUNDS AND METHODS OF MODULATING CELL-ADHESION
MEDIATED DRUG RESISTANCE

INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97(b)

Honorable Commissioner for Patents
Washington, D.C. 20231

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application. Copies of the listed documents, including any copending patent applications, are attached. A copy of the International Search Report is also attached. Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the

Atty: Docket No.: 215101.01501
Customer No. 27160

PATENT
Serial No.: 10/024,017

documents as prior art against any claim in the application and applicants determine that the cited documents do not constitute "prior art" under United States law, applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 50-0436.

Respectfully submitted,

Gilberto M. Villacorta, Ph.D.
Registration No. 34,038

by


Gianna Julian Arnold
Registration No. 36,358

Attention Patent Administrator
KATTEN MUCHIN ZAVIS ROSENMAN
525 West Monroe Street, Suite 1600
Chicago, IL 60661-3693
FAX: (312) 902-1061
(202) 625-3500

Date: April 22, 2002

INFORMATION DISCLOSURE CITATION

OMB No. 0651-0011

RECEIVED

Atty. Docket No. 215101.01501	Appln. No. 10/024,017
Applicants William S. DALTON et al.	
Filing Date December 21, 2001	Group: 1646

APR 24 2002

U.S. PATENT DOCUMENTS							
Examiner Initials	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate	

TECH CENTER 1600/2900

FOREIGN-PATENT DOCUMENTS							
	Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	Damiano et al., J.S., "Cell Adhesion Mediated Drug Resistance (CAM-DR): Role of Integrins and Resistance to Apoptosis in Human Myeloma Cell Lines," <u>Blood</u> , Vol. 93, No. 5 (March 1999), pp. 1658-67.
	Pennington et al., M.E., "The Use of a Combinatorial Library Method to Isolate Human Tumor Cell Adhesion Peptides," <u>ESCOM Science Publishers: Molecular Diversity</u> , Vol. 2 (1996), pp. 19-28.
	Hazlehurst et al., L.A., "Adhesion to Fibronectin via $\beta 1$ Integrins Regulates p27 ^{kip1} Levels and Contributes to Cell Adhesion Mediated Drug Resistance (CAM-DR)," <u>Oncogene</u> , (Nov. 2001), pp. 011/012-003/012.
	DeRoock et al., I.B., <u>Synthetic Peptides Inhibit Adhesion of Human Tumor Cells to Extracellular Matrix Proteins</u> , <u>Cancer Research</u> , Vol. 61 (April 2001), pp. 3308-3313.

Examiner	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449 Patent and Trademark Office - U.S. Department of Commerce	